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AbstrACt
Introduction Gout is the most common inflammatory 
arthritis in the Dutch general practice population and 
is often managed with long-term uric acid lowering 
treatment. The clinical relevance of this treatment in 
preventing gout attacks is unclear.
Primary research question What is the frequency 
of self-reported gout attacks and what is the effect 
of allopurinol use in patients diagnosed with gout in 
general practice?
Methods and analysis Adult patients with a 
diagnostic consultation code for gout in the year 2013, 
2014 or 2015 will be invited to participate in this 
prospective observational cohort study. Patients with 
a limited life expectancy will be excluded. Baseline 
measurements will include blood pressure, body 
mass index and a blood sample (estimated glomerular 
filtration rate, serum uric acid, cholesterol (low-density 
lipoprotein (LDL) and high-density lipoprotein), glucose 
(fasting)). At the 2-year follow-up, patients will receive 
questionnaires every 3 months. The questionnaires 
at baseline, 12 months and 24 months assess the 
frequency of gout attacks, the presence of tophi, 
comorbidity, medication use, quality of life, diet and 
lifestyle. The questionnaires in between only assess the 
frequency of gout attacks and medication use for gout. 
Descriptive statistics will be used to calculate the mean 
frequency of self-reported gout attacks during the 
2-year follow-up. The propensity score for each patient 
being offered allopurinol is estimated and used to 
match patients with and without allopurinol treatment. 
We will compare the frequency of gout attacks in these 
groups using multilevel Poisson regression analyses. 
With this type of analysis, we can calculate the 
corrected estimated effect of allopurinol on gout attack 
frequency.
Ethics and dissemination The research protocol was 
approved by the Medical Ethical Committee of the Erasmus 
Medical Centre in Rotterdam. The knowledge generated by 
this study will be transferred to the Dutch College of General 
Practitioners, conferences and to (inter)national peer-reviewed 
journals.
trial registration number NTR6329; Pre-results.
IntroduCtIon 
background and rationale
Gout is the most common inflammatory 
arthritis, affecting 1.7% of the total Dutch 
general practice population, and 3%–4% of the 
adult population.1 Acute gout is one of the most 
painful forms of arthritis and is characterised by 
the abrupt onset of severe joint pain (classically 
the first metatarsophalangeal joint), swelling 
and erythema. It is caused by the deposition of 
monosodium uric acid crystals in and around 
joints, leading to an aseptic arthritis. The 
appearance of such crystal deposition is strongly 
associated with a raised serum uric acid concen-
tration (hyperuricaemia). However, although 
there is a clear association between hyperuri-
caemia and gout, only a minority of people with 
hyperuricaemia actually go on to develop gouty 
strengths and limitations of this study
 ► This study will recruit and follow-up patients in a 
large primary care population, providing important 
information about gout attack frequencies, risk fac-
tors and treatment of gout in general practice.
 ► Gout diagnosis is based on the interpretation of gener-
al practitioners, American College of Rheumatology/
European League Against Rheumatism criteria and 
the gout calculator rather than synovial fluid analysis 
for the presence of monosodium urate crystals, the 
current gold standard for gout diagnosis.
 ► Evaluating the effect of allopurinol treatment as pre-
scribed in daily practice will result in a much higher 
generalisability and improve feasibility when com-
pared with performing an randomised controlled 
trial.
 ► In our sample of patients with prevalent gout, there 
may be variation in treatment duration of allopuri-
nol. If treatment duration of allopurinol is associated 
with the number of experienced gout attacks then 
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arthritis.2 In practice, gout is often managed with (lifelong) 
uric acid-lowering medication, most often allopurinol. There 
is limited evidence that it actually reduces the gout attack 
frequency and/or resolves tophi if present, or prevents long-
term joint damage.3 Randomised trials have only provided 
evidence on serum uric acid concentrations, a surrogate 
outcome, and not on clinical endpoints.3 In addition, there 
is much debate on the indications for, and best time to start 
with long-term uric acid lowering therapy.4 Although allo-
purinol treatment is recommended by American College of 
Rheumatology (ACR) and European League Against Rheu-
matism (EULAR) guidelines, recently the American College 
of Physicians recommended against initiating long-term 
urate-lowering therapy in patients with infrequent attacks.5 
Other risk factors, which are traditionally thought to play a 
causal role in the development of gout include diet, over-
weight and use of medication, but the exact mechanisms 
by which these might lead to gout or might be associated 
with gout attack frequency are unclear. Recent studies show 
contradictory of inconclusive results.6–9 
objectives
The primary objective of this cohort study is to measure the 
frequency of self-reported gout attacks and the prevalence 
of tophi in patients diagnosed with gout in general practice, 
and to assess whether the use of allopurinol decreases the 
self-reported gout attack frequency and the prevalence of 
tophi.
Secondary objectives of this study are: (1) to assess 
whether patient characteristics and lifestyle factors (such 
as the presence of cardiovascular risk factors, body mass 
index (BMI), smoking status, physical activity and social 
status) are associated with the self-reported frequency of 
gout attacks; (2) to assess whether the consumption of 
fructose rich beverages, carbonated beverages, alcohol, 
purine rich food, lactose and dairy products are associ-
ated with the self-reported frequency of gout attacks; (3) 
to assess whether the use of medication, such as diuretics 
and salicylates, is associated with gout attack frequency.
study design
Multicentre prospective observational cohort study of 
patients diagnosed with gout in general practice. The 
coordinating centre is the department of general prac-
tice, Erasmus Medical Centre.
MEthods And AnAlysIs
study setting
The study will be conducted in the primary care commu-
nity in the Netherlands.
study population
Inclusion criteria
Patients, 18 years or older, with at least one gout attack 
between January 2013 and December 2015 as diagnosed 
by his or her general practitioner (GP), will be screened 
for eligibility.
Exclusion criteria
Patients with a limited life expectancy and patients who 
(independently or with help) are not able to fill in the 
Dutch questionnaires will be excluded.
Patient selection and recruitment
Potential eligible patients will be anonymously selected from 
the Integrated Primary Care Information (IPCI) database: 
a longitudinal primary healthcare database.10 This database 
contains the electronic patient records of over 1.5 million 
patients registered with over 700 GPs throughout the Nether-
lands. It contains all journal entries by the GP, coded diagnoses 
using the International Classification of Primary Care (ICPC) 
codes, referrals, clinical findings by specialists, laboratory 
findings and hospitalisations.11 Episodes of gout will be iden-
tified based on ICPC-coding (T92) and free text (gout). The 
patient’s identity in the IPCI-database is anonymised. However, 
all patients in the IPCI-database have a unique patient identity 
code which can only be decrypted by their GP. Every GP in 
the database has a unique GP identity code which can only 
be decrypted by the database gatekeeper. The gatekeeper will 
provide participating GPs with a list of unique identity codes 
of the selected patients. The GP is able to decrypt the code 
and will assess whether the patient is eligible according to the 
inclusion and exclusion criteria. Eligible patients will receive 
written information and an informed consent form from the 
GP. They will be requested to send their contact details to the 
research centre if they are willing to participate. A telephonic 
interview will take place to answer any questions the patient 
has, followed by the informed consent procedure. To improve 
the response rate, reminders will be sent to general practices 
and eligible patients.
sample size calculation
With a significance level of 0.05 and a power of 0.99, we 
are able to detect a difference in an average number of 2.8 
attacks in the untreated and of 1.4 in the treated group when 
we include 227 patients using allopurinol and perform a 
1:2 matching. Our explorative search in the IPCI database 
in 2016 indicated that about one-third of the patients diag-
nosed with gout by the GP use allopurinol. This would mean 
that we at least have to include 681 patients with gout (227 
allopurinol users and 454 non-users). When the treatment 
effect is substantially lower with 2.8 in the untreated and 2.4 
in the treated patients, we still have a power of 0.85 to detect 
this difference with the same level of significance. Equally, 
this high power allows exclusion of up to 40% non-match-
able patients (in case of 1:2 matching and 2.8 vs 1.4 attacks 
in the different groups). Finally, to account for 10% poten-
tial loss to follow-up, we aim to include at least 757 patients.
study outcomes
The outcomes are the frequency of self-reported gout 
attacks per year and the prevalence of tophi in patients 
diagnosed with gout in general practice.
data collection and research measures
Clinical measurements
At baseline, a blood sample and a physical examination 
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examination of estimated glomerular filtration rate 
(eGFR), uric acid level, total cholesterol, low-density and 
high-density lipoprotein cholesterol and fasting glucose. 
All patients will be asked to visit their GP for a physical 
examination to obtain a standardised blood pressure 
(the average blood pressure of three measurements), 
and measurement of height and weight to calculate the 
BMI. These factors contribute to an approximation of the 
cardiovascular risk and general health.
Patient demographics
At baseline age, gender, marital status, level of education 
and current occupation will be recorded.
Gout attacks
In a baseline questionnaire, the presence of gout will be 
validated according to the 2015 ACR-EULAR criteria for 
gout and the diagnostic rule (Gout calculator).12 13 The 
date of the first gout attack, the lifetime number of gout 
attacks, characteristics of the most recent gout attack 
such as localisation and severity of the attack, and all 
medication use related to gout will be evaluated. These 
factors contribute to the indication for allopurinol treat-
ment according to the Dutch primary care guidelines.1 
The gout attack frequency (including localisation and 
severity of the most recent gout attack and all medication 
use related to gout and adherence) will be repeatedly 
evaluated every 3 months in follow-up questionnaires. In 
the questionnaires, a gout attack is defined as the time a 
joint is painful or swollen because of gout. To measure 
the disease-specific impact and consequences of gout, the 
validated Gout Assessment Questionnaire 2.0 will be used 
at baseline, and at 1-year and 2-year follow-ups.14–16
Presence of tophi
The patient-reported presence of tophi and the physical 
and mental burden of tophi will be determined at base-
line, after 3 months, 1 year and 2 years follow-up, using 
the Tophus Impact Questionnaire-20.17 Explanatory text 
and images of tophi are presented in the questionnaire. 
The time point at 3 months follow-up was chosen to vali-
date the questionnaire for the Dutch language, since this 
was not previously done. The time points at 1 and 2 years 
follow-up were chosen to measure changes in the pres-
ence and burden of tophi.
Comorbidity
Comorbidity will be assessed at baseline, 1 year and 
2 years follow-up using the Self-administered Comorbidity 
Questionnaire.18
Physical and mental health
Physical and mental health will be determined at base-
line, 1 year and 2 years using the Short Form-36 phys-
ical and mental component summary and quality of life 
via the EuroQol 5 dimensions.19 20 Physical activity will 
be measured with the International Physical Activity 
Questionnaire.21
Medication use
The use of all prescribed and over-the-counter medi-
cation will be measured at baseline, 1 year and 2 years 
follow-up using a derived version of the Brief Medication 
Questionnaire.22
Diet and smoking
Dietary intake will be measured using the Dutch Food 
Frequency Questionnaire.23–26 This validated question-
naire inventories all dietary habits over the past month 
and will be administered at baseline, 1 and 2 years 
follow-up. Smoking status will be asked every year.
All data collection and time points are pictured in 
table 1. A patient time line is presented in figure 1.
The questionnaires will be electronically mailed to the 
patients using GemsTracker (GEneric Medical Survey 
Tracker). This is a software package for (complex) 
distribution of questionnaires and forms during clinical 
research and quality registrations in healthcare. Patients 
not able to work with a computer receive the question-
naires on paper. The deadline of each questionnaire is 
4 weeks. Patients are reminded after 1 week (email), 
2 weeks (telephone call) and 3 weeks (email). If a ques-
tionnaire is not filled out, it is recorded as missing.
data analysis
The frequency of gout attacks and the prevalence of 
tophi will be calculated by means of descriptive statistics. 
To investigate the association between the use of allo-
purinol and the frequency of self-reported gout attacks, 
and respectively, the presence of tophi, we will use 
Poisson regression analyses, adjusted and unadjusted for 
risk factors for attack frequency. Before Poisson regres-
sion analysis, we will apply a propensity score matching 
analysis with calliper matching. First, the conditional 
probability that the patient will be offered allopurinol 
treatment will be estimated for each patient, based on a 
number of important factors. To identify these factors, 
binary logistic regression analyses will be conducted with 
allopurinol treatment (yes/no) as dependent and each 
potential confounder as independent variable. Selected 
potential confounders (expected to be related to the 
severity of gout) are: the presence of tophi, renal func-
tion (eGFR), blood pressure at baseline, time since gout 
diagnosis and the previous number of gout attacks per 
year. Other potential confounders are: age, gender, social 
status, baseline uric acid level (above or below target 
level of 0.35 mmol/L), BMI, smoking behaviour, phys-
ical activity, presence of comorbidity and consumption 
of alcohol and purine rich food. Variables with a p value 
smaller than 0.10 will be selected for the estimation of 
the propensity score. Subsequently, the derived propen-
sity scores will be used for one-to-many matching, where 
patients with allopurinol treatment are matched to as 
many patients as possible without allopurinol treatment. 
These matched groups will be selected using nearest 
neighbour matching, with no replacement. To ensure 
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restriction, known as calliper matching, will be imposed 
to ensure that the propensity scores of control patients 
(without allopurinol treatment) lie within a prespecified 
interval of the propensity score of their matched case. 
All patients without appropriate matched patients in the 
other group will be excluded from the matched sample. 
To assess whether the matched sample is balanced, the 
characteristics of both groups will be compared before 
and after propensity score matching. Then, a corrected 
estimated effect of allopurinol will be calculated using 
a multilevel Poisson regression analysis, in which the 
propensity score is used as a matching variable. Potential 
confounders will be added to the regression model, such 
as time from first allopurinol use and serum urate level 
at baseline.
To answer the secondary objectives, associations will 
be estimated using multivariable logistic regression anal-
ysis. The dependent variable will be patients’ reported 
Table 1 Summary of data collection and timeline
Data collection
Timeline (months from baseline)
0 3 6 9 12 15 18 21 24
Physical examination (blood 
pressure, height, weight)
X
Laboratory serum examination: 




Gout attacks: frequency, 
characteristics, medication use and 
adherence (GAQ)
X X X X X X X X X
Presence and burden of tophi (TIQ-
20)
X X X X
Comorbidity (SCQ) X X X
Physical and mental health (SF-36) 
and physical activity (IPAQ)
X X X
Quality of life (EQ-5D) X X X
Medication use (general) (BMQ) X X X
Diet (FFQ) and smoking status X X X
BMQ, Brief Medication Questionnaire; eGFR, estimated glomerular filtration rate; EQ-5D, EuroQol 5 Dimensions; FFQ, Food Frequency 
Questionnaire; GAQ, Gout Assessment Questionnaire; HDL, high-density lipoprotein cholesterol; IPAQ, International Physical Activity 
Questionnaire; LDL, low-density lipoprotein cholesterol; SCQ, Self-administered Comorbidity Questionnaire; SF-36, Short Form health survey; 
TC, total cholesterol; TIQ-20, Tophus Impact Questionnaire 20.
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frequency of gout attacks. The covariates will be patient 
characteristics, physical and mental health, medication 
use and dietary habits.
data monitoring
Participating in the study results in negligible risks for 
the participating patients. All study centres will be moni-
tored once every year. The monitoring includes study 
documents and agreements, patient inclusion, consent, 
compliance and source document verification, verifica-
tion of all study procedures and the certification of the 
participating laboratories. All auditing will be indepen-
dent from the investigators and the sponsor.
Patients and public involvement
No patients were involved in the development of research 
questions, design or conduct of this study. The results will 
be disseminated to all study participants through a digital 
(or paper if requested) newsletter.
EthICs And dIssEMInAtIon
The study is registered in the Dutch Trial Register. In case 
of any changes or modifications to the research protocol, 
the sponsor and the medical ethical committee will be 
informed.
The researcher will obtain written informed consent 
from potential participants before enrolment in the study. 
A liability insurance is provided covering any harm incurred 
by patients during the course of the study. However, the 
study poses no to negligible risk to participating patients. 
Patients’ identity will remain confidential at all times. Each 
patient will be given a unique code number which will be 
used on the case report forms and in the database. Only 
the researchers have access to the file of the names and 
corresponding code numbers of the patients. Results from 
the blood samples are reported via fax machine and stored 
digitally, all other information from enrolled participants 
will be collected using paper or digital questionnaires and 
will be digitally stored in a password-protected environment. 
Only the executive researcher, project leader and principal 
investigator have access to the final trial dataset. There are 
no contractual agreements with the study sponsor that limit 
access for the investigators. The generated knowledge by 
this study will be transferred to the Dutch College of General 
Practitioners (NHG) and other disciplines treating patients 
with gout including rheumatologists. The study will provide 
important information about risk factors and treatment of 
gout in general practice, when updating the clinical NHG 
guideline M90 ‘Arthritis’ in the future. For this purpose, 
we will approach the NHG Steering Committee actively 
with our results. We will also report the results to the Dutch 
Arthritis Foundation and to the Dutch Association for Rheu-
matology. In addition to the usual international peer-review 
publications of the results, we will publish the results of 
the study in national journals distributed among GPs and 
other relevant disciplines. Also, we will report the results at 
(inter)national congresses, and during regional meetings 
for involved disciplines. No data sharing arrangements have 
been made, and there are no publication restrictions by the 
study sponsor.
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